Insulet reports Q1 net income of US$27.8M from US$0.0M a year ago, with revenue up 17.1% year-over-year at US$295.4M; US revenue of Omnipod 5 automated insulin delivery system up 21.5% after limited launch in country, with full market release this year

Sample article from our Health Care Sector

ACTON, Massachusetts , May 9, 2022 (press release) –

Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced financial results for the three months ended March 31, 2022.

First Quarter Financial Highlights:

  • First quarter 2022 revenue of $295.4 million, up 17.1%, or 19.3% in constant currency, compared to $252.3 million in the prior year, exceeds the guidance range of 13% to 16% in constant currency
  • Total Omnipod revenue of $269.5 million, an increase of 15.6%, or 18.0% in constant currency
  • U.S. Omnipod revenue of $174.1 million, an increase of 21.5%
  • International Omnipod revenue of $95.4 million, an increase of 6.1%, or 12.5% in constant currency
  • Drug Delivery revenue of $25.9 million, an increase of 35.6%
  • Gross margin of 71.0%, up 460 basis points
  • Operating income of $37.9 million, or 12.8% of revenue, compared to operating income of $16.3 million, or 6.5% of revenue, in the prior year
  • Net income of $27.8 million, or $0.40 per diluted share, compared to $0.0 million, or $0.00 per diluted share, in the prior year
  • Adjusted EBITDA1 of $63.0 million, or 21.3% of revenue, compared to $35.1, or 13.9% of revenue, in the prior year

Recent Strategic Highlights:

  • U.S. limited commercial launch of the Omnipod® 5 Automated Insulin Delivery System (Omnipod 5) continues to ramp; on track for a full market release this year
  • Achieved record first quarter U.S. and Total Omnipod new customer starts
  • Presented type 2 feasibility study data at the Advanced Technologies & Treatments for Diabetes (ATTD) conference demonstrating Omnipod 5 significantly improved time in range and reduced HbA1c, while also reducing hypoglycemia and total daily dose of insulin for participants previously on multiple daily injections
  • Launched Omnipod DASH® in Saudi Arabia and expect to launch soon in the United Arab Emirates
  • Advanced sustainability across the Company, as detailed in Insulet’s 2021 Sustainability Report2

_______________________________________________
1 See description of non-GAAP financial measures contained in this release.
2 Insulet’s 2021 Sustainability report can be found at: 2021 Sustainability Report.

“We are off to a great start in 2022 with first quarter financial results that reflect strong global Omnipod adoption, consumer satisfaction and operational excellence, positioning the Company for another successful year,” said Shacey Petrovic, President and Chief Executive Officer. “The commercial launch of Omnipod 5 is progressing very well, and we are receiving excellent customer feedback. We also recently shared compelling type 2 feasibility data that demonstrates how powerful Omnipod 5 can be for this dramatically underserved population. Momentum across our business continues to grow and our mission to simplify and improve the lives of people with diabetes remains at the center of everything we do.”

2022 Outlook:

Revenue Guidance (in constant currency):

  • For the year ending December 31, 2022, the Company is reaffirming its expected revenue growth of 12% to 16%. Revenue growth ranges by product line are:
    • Total Omnipod of 16% to 20% (previously 15% to 20%)
      • U.S. Omnipod of 19% to 23% (previously 18% to 23%)
      • International Omnipod of 9% to 14% (unchanged)
    • Drug Delivery of (35)% to (30)% (unchanged)
  • For the quarter ending June 30, 2022, the Company expects revenue growth of 12% to 15%. Revenue growth ranges by product line are:
    • Total Omnipod of 17% to 20%
      • U.S. Omnipod of 21% to 24%
      • International Omnipod of 9% to 12%
    • Drug Delivery of (43)% to (37)%

Operating Margin Guidance:

For the year ending December 31, 2022, the Company now expects operating margin to be flat year-over-year as a result of the macro environment and higher inflationary, supply chain, and foreign exchange pressures.

Conference Call:

Insulet will host a conference call at 4:30 p.m. (Eastern Time) on May 5, 2022 to discuss the financial results and outlook. The link to the live call will be available on the Investor Relations section of the Company’s website at investors.insulet.com, “Events and Presentations,” and will be archived for future reference.

About Insulet Corporation:

Insulet Corporation (NASDAQ: PODD), headquartered in Massachusetts, is an innovative medical device company dedicated to simplifying life for people with diabetes and other conditions through its Omnipod product platform. The Omnipod Insulin Management System provides a unique alternative to traditional insulin delivery methods. With its simple, wearable design, the disposable Pod provides up to three days of non-stop insulin delivery, without the need to see or handle a needle. Insulet's latest innovation, the Omnipod® 5 Automated Insulin Delivery System, is a tubeless automated insulin delivery system, integrated with a continuous glucose monitor to manage blood sugar with no multiple daily injections, zero fingersticks, and is fully controlled by a compatible personal smartphone. Insulet also leverages the unique design of its Pod by tailoring its Omnipod technology platform for the delivery of non-insulin subcutaneous drugs across other therapeutic areas. For more information, please visit: insulet.com and omnipod.com.

Non-GAAP Measures:

The Company uses the following non-GAAP financial measures:

  • Constant currency revenue growth, which represents the change in revenue between current and prior year periods using the exchange rate in effect during the applicable prior year period. Insulet presents constant currency revenue growth because management believes it provides meaningful information regarding the Company’s results on a consistent and comparable basis. Management uses this non-GAAP financial measure, in addition to financial measures in accordance with generally accepted accounting principles in the United States (GAAP), to evaluate the Company’s operating results. It is also one of the performance metrics that determines management incentive compensation.
  • Adjusted EBITDA, which represents net income (loss) plus net interest expense, income tax expense (benefit), depreciation and amortization, stock-based compensation and other significant unusual items, as applicable; and Adjusted EBITDA as a percentage of revenue. Insulet presents these non-GAAP financial measures because management uses them as supplemental measures in assessing the Company’s operating performance, and the Company believes that they are helpful to investors, and other interested parties as measures of comparative operating performance from period to period. They also are commonly used measures in determining business value and the Company uses them internally to report results.

These non-GAAP financial measures should be considered supplemental to, and not a substitute for, the Company’s reported financial results prepared in accordance with GAAP. Furthermore, the Company’s definition of these non-GAAP measures may differ from similarly titled measures used by others. Because non-GAAP financial measures exclude the effect of items that will increase or decrease the Company’s reported results of operations, Insulet strongly encourages investors to review the Company’s consolidated financial statements and publicly filed reports in their entirety.

Forward-Looking Statement:

This press release contains forward-looking statements regarding, among other things, future operating and financial performance, product success and efficacy, the outcome of studies and trials and the approval of products by regulatory bodies. These forward-looking statements are based on management’s current beliefs, assumptions and estimates and are not intended to be a guarantee of future events or performance. If management’s underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by the forward-looking statements.

Risks and uncertainties include, but are not limited to adverse changes in general economic conditions as well as risks associated with public health crises and pandemics, such as the COVID-19 global pandemic, government actions and restrictive measures implemented in response, supply chain disruptions, delays in clinical trials, and other impacts to the business; dependence on a principal product platform; ability to maintain and grow our customer base; ability to scale the business to support revenue growth; maintenance of an effective sales force and expansion of distribution network; ability to secure and retain adequate coverage or reimbursement from third-party payors; impact of healthcare reform laws; impact of competitive products, technological change and product innovation; ability to design, develop, manufacture and commercialize future products; changes to or termination of our license to incorporate a blood glucose meter into the Omnipod System or inability to enter into new license or other agreements with respect to the Omnipod System’s current or future features; challenges to the future development of our non-insulin drug delivery product line; international business risks, including regulatory, commercial and logistics risks; supply problems or price fluctuations with sole source or third-party suppliers on which we are dependent; failure to retain key suppliers and/or supplier pricing discounts and achieve satisfactory gross margins; ability to protect our intellectual property and other proprietary rights and potential conflicts with the intellectual property of third parties; adverse regulatory or legal actions relating to the Omnipod System or future products; failure of our contract manufacturer or component suppliers to comply with the U.S. Food and Drug Administration’s quality system regulations; potential adverse impacts resulting from a recall, or discovery of serious safety issues, or product liability lawsuits relating to off-label use; the potential violation of anti-bribery/anti-corruption laws or laws and regulations regarding privacy and data protection; breaches or failures of our product or information technology systems, including by cyberattack; unfavorable results of clinical studies or future publication of articles or announcement of positions by diabetes associations or other organizations that are unfavorable; the concentration of manufacturing operations and storage of inventory in a limited number of locations; loss of employees or inability to identify and recruit new employees; ability to generate sufficient cash to service our indebtedness or raise additional funds on acceptable terms or at all; the volatility of the trading price of our common stock; risks related to the conversion of outstanding Convertible Senior Notes; and potential limitations on our ability to use net operating loss carryforwards.

For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item 1A - Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A - Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file hereafter. Any forward-looking statement made in this release speaks only as of the date of this release. Insulet does not undertake to update any forward-looking statement, other than as required by law.

©2022 Insulet Corporation. Omnipod, Omnipod DASH and Omnipod 5 are registered trademarks of Insulet Corporation.

INSULET CORPORATION

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)

   

 

Three Months Ended March 31,

(dollars in millions, except per share data)

 

2022

 

 

 

2021

 

Revenue

$

295.4

 

 

$

252.3

 

Cost of revenue

 

85.7

 

 

 

84.8

 

Gross profit

 

209.7

 

 

 

167.5

 

Research and development expenses

 

43.1

 

 

 

40.7

 

Selling, general and administrative expenses

 

128.7

 

 

 

110.5

 

Operating income

 

37.9

 

 

 

16.3

 

Interest expense, net

 

(8.9

)

 

 

(13.4

)

Other income (expense), net

 

0.3

 

 

 

(2.6

)

Income before income taxes

 

29.3

 

 

 

0.3

 

Income tax expense

 

(1.5

)

 

 

(0.3

)

Net income

$

27.8

 

 

$

 

 

 

 

 

Net income per share:

 

 

 

Basic

$

0.40

 

 

$

 

Diluted

$

0.40

 

 

$

 

Weighted-average number of common shares outstanding (in thousands):

 

 

 

Basic

 

69,254

 

 

 

66,113

 

Diluted

 

69,858

 

 

 

66,113

 

 

INSULET CORPORATION

CONDENSED CONSOLIDATED BALANCE SHEET (UNAUDITED)

   

 

As of

 

March 31,

 

 December 31,

(dollars in millions)

2022

 

2021

ASSETS

 

 

 

Cash and cash equivalents

$

709.6

 

$

791.6

Accounts receivable, net

 

189.3

 

 

161.0

Inventories

 

314.8

 

 

303.2

Prepaid expenses and other current assets

 

71.7

 

 

74.0

Total current assets

 

1,285.4

 

 

1,329.8

Property, plant and equipment, net

 

538.2

 

 

536.5

Goodwill and other intangible assets, net

 

104.6

 

 

76.4

Other assets

 

141.0

 

 

106.1

Total assets

$

2,069.2

 

$

2,048.8

LIABILITIES AND STOCKHOLDERS’ EQUITY

 

 

 

Accounts payable

$

52.2

 

$

37.7

Accrued expenses and other current liabilities

 

137.1

 

 

166.0

Current portion of long-term debt

 

25.7

 

 

25.1

Total current liabilities

 

215.0

 

 

228.8

Long-term debt, net

 

1,390.5

 

 

1,248.8

Other liabilities

 

17.0

 

 

14.9

Total liabilities

 

1,622.5

 

 

1,492.5

Stockholders’ equity

 

446.7

 

 

556.3

Total liabilities and stockholders’ equity

$

2,069.2

 

$

2,048.8

INSULET CORPORATION

NON-GAAP RECONCILIATIONS (UNAUDITED)

 

CONSTANT CURRENCY REVENUE GROWTH

 

Three Months Ended March 31,

 

 

 

 

 

 

(dollars in millions)

 

2022

 

 

2021

 

Percent Change

 

Currency

Impact

 

Constant

Currency

Revenue:

 

 

 

 

 

 

 

 

 

U.S. Omnipod

$

174.1

 

$

143.3

 

21.5

%

 

%

 

21.5

%

International Omnipod

 

95.4

 

 

89.9

 

6.1

%

 

(6.4

) %

 

12.5

%

Total Omnipod

 

269.5

 

 

233.2

 

15.6

%

 

(2.4

) %

 

18.0

%

Drug Delivery

 

25.9

 

 

19.1

 

35.6

%

 

%

 

35.6

%

Total

$

295.4

 

$

252.3

 

17.1

%

 

(2.2

) %

 

19.3

%

ADJUSTED EBITDA

   

 

Three Months Ended March 31,

(dollars in millions)

2022

 

Percent of

Revenue

 

2021

 

Percent of

Revenue

Net income

$

27.8

 

9.4

%

 

$

 

%

Interest expense, net

 

8.9

 

 

 

 

13.4

 

 

Income tax expense

 

1.5

 

 

 

 

0.3

 

 

Depreciation and amortization

 

15.3

 

 

 

 

12.8

 

 

Stock-based compensation

 

9.5

 

 

 

 

8.6

 

 

Adjusted EBITDA

$

63.0

 

21.3

%

 

$

35.1

 

13.9

%

INSULET CORPORATION

REVENUE GUIDANCE RECONCILIATIONS (UNAUDITED)

   

 

Year Ending December 31, 2022

 

Low

 

High

 

Revenue
Growth
GAAP

 

Currency
Impact

 

Constant
Currency

 

Revenue
Growth
GAAP

 

Currency
Impact

 

Constant
Currency

U.S. Omnipod

19 %

 

— %

 

19 %

 

23 %

 

— %

 

23 %

International Omnipod

— %

 

(9) %

 

9 %

 

5 %

 

(9) %

 

14 %

Total Omnipod

13 %

 

(3) %

 

16 %

 

17 %

 

(3) %

 

20 %

Drug Delivery

(35) %

 

— %

 

(35) %

 

(30) %

 

— %

 

(30) %

Total

9 %

 

(3) %

 

12 %

 

13 %

 

(3) %

 

16 %

 

Three Months Ended June 30, 2022

 

Low

 

High

 

Revenue
Growth
GAAP

 

Currency
Impact

 

Constant
Currency

 

Revenue
Growth
GAAP

 

Currency
Impact

 

Constant
Currency

U.S. Omnipod

21 %

 

— %

 

21 %

 

24 %

 

— %

 

24 %

International Omnipod

(2) %

 

(11) %

 

9 %

 

1 %

 

(11) %

 

12 %

Total Omnipod

13 %

 

(4) %

 

17 %

 

16 %

 

(4) %

 

20 %

Drug Delivery

(43) %

 

— %

 

(43) %

 

(37) %

 

— %

 

(37) %

Total

8 %

 

(4) %

 

12 %

 

11 %

 

(4) %

 

15 %

 

View source version on businesswire.comhttps://www.businesswire.com/news/home/20220504005975/en/

Investor Relations:

Deborah R. Gordon
Vice President, Investor Relations
(978) 600-7717
dgordon@insulet.com

Media:

Angela Geryak Wiczek
Senior Director, Corporate Communications
(978) 932-0611
awiczek@insulet.com

Source: Insulet Corporation

 

 

 

 

 

 

 

 

 

* All content is copyrighted by Industry Intelligence, or the original respective author or source. You may not recirculate, redistrubte or publish the analysis and presentation included in the service without Industry Intelligence's prior written consent. Please review our terms of use.

See our dashboard in action - schedule an demo
Dan Rivard
Dan Rivard
- VP Market Development -

We offer built-to-order health care sector coverage for our clients. Contact us for a free consultation.

About Us

We deliver market news & information relevant to your business.

We monitor all your market drivers.

We aggregate, curate, filter and map your specific needs.

We deliver the right information to the right person at the right time.

Our Contacts

1990 S Bundy Dr. Suite #380,
Los Angeles, CA 90025

+1 (310) 553 0008

About Cookies On This Site

We collect data, including through use of cookies and similar technology ("cookies") that enchance the online experience. By clicking "I agree", you agree to our cookies, agree to bound by our Terms of Use, and acknowledge our Privacy Policy. For more information on our data practices and how to exercise your privacy rights, please see our Privacy Policy.